UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2019
Commission File Number:001-38547
Autolus Therapeutics plc
(Translation of registrant’s name into English)
Forest House
58 Wood Lane
White City
London W12 7RZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Other Events
Press Release
On March 26, 2019, Autolus Therapeutics plc (the “Company”) issued a press release announcing its inaugural R&D Day to be held on March 26, 2019 in New York. At its R&D Day, the Company presented an update on its AUTO3 program in pediatric acute lymphocytic leukemia. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
Information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Autolus Therapeutics plc | ||||||
Date: March 27, 2019 | By: | /s/ Christian Itin | ||||
Name | Christian Itin, Ph.D. | |||||
Title: | Chief Executive Officer |